Perspective Therapeutics (NYSE:CATX) Raised to Strong-Buy at Brookline Capital Management

Brookline Capital Management upgraded shares of Perspective Therapeutics (NYSE:CATX) to a strong-buy rating in a research report released on Monday,Zacks.com reports.

A number of other brokerages also recently commented on CATX. Lifesci Capital upgraded shares of Perspective Therapeutics to a “strong-buy” rating in a report on Thursday, March 6th. Bank of America lowered shares of Perspective Therapeutics from a “buy” rating to a “neutral” rating and reduced their price objective for the stock from $24.00 to $5.00 in a research note on Monday, November 25th. Oppenheimer decreased their target price on shares of Perspective Therapeutics from $22.00 to $16.00 and set an “outperform” rating for the company in a research report on Friday, November 22nd. Scotiabank started coverage on shares of Perspective Therapeutics in a report on Friday. They issued a “sector outperform” rating and a $15.00 price target on the stock. Finally, Wedbush reiterated an “outperform” rating and set a $11.00 price objective on shares of Perspective Therapeutics in a report on Friday, January 24th. One research analyst has rated the stock with a hold rating, seven have given a buy rating and three have issued a strong buy rating to the company’s stock. According to data from MarketBeat, Perspective Therapeutics currently has a consensus rating of “Buy” and a consensus target price of $15.13.

Perspective Therapeutics Trading Down 2.7 %

Shares of NYSE:CATX opened at $2.54 on Monday. Perspective Therapeutics has a 12-month low of $2.32 and a 12-month high of $19.05. The business’s fifty day simple moving average is $3.20 and its 200-day simple moving average is $7.57.

Hedge Funds Weigh In On Perspective Therapeutics

Several hedge funds have recently made changes to their positions in CATX. US Bancorp DE grew its stake in Perspective Therapeutics by 142.7% during the 3rd quarter. US Bancorp DE now owns 6,576 shares of the company’s stock valued at $88,000 after purchasing an additional 3,866 shares during the last quarter. Y Intercept Hong Kong Ltd acquired a new stake in shares of Perspective Therapeutics during the fourth quarter worth about $33,000. Intech Investment Management LLC purchased a new stake in Perspective Therapeutics in the third quarter valued at approximately $137,000. Aigen Investment Management LP acquired a new position in Perspective Therapeutics in the 4th quarter worth approximately $34,000. Finally, National Bank of Canada FI raised its position in Perspective Therapeutics by 549,900.0% during the 4th quarter. National Bank of Canada FI now owns 11,000 shares of the company’s stock worth $35,000 after buying an additional 10,998 shares during the last quarter. 54.66% of the stock is owned by institutional investors and hedge funds.

Perspective Therapeutics Company Profile

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.